共 23 条
[1]
Chan, Deboer, Thorner, Et al., Multidrug-resistance. Clinical opportunities in diagnosis and circumvention, Hemat Oncol Clin N Am, 8, pp. 383-410, (1994)
[2]
Lum, Gosland, Kaubisch, Sikic, Molecular targets in oncology: implications of the multidrug resistance gene, Pharmacotherapy, 13, pp. 88-109, (1993)
[3]
Raderer, Scheithauer, Clinical trials of agents that reverse multidrug resistance, Cancer, 72, pp. 3553-3563, (1993)
[4]
Keller, Altermatt, Donatsch, Et al., Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16–213) enhance in vivo cytostatic activity and toxicity, Int J Cancer, 51, pp. 433-438, (1992)
[5]
Sikic, Modulation of multidrug resistance: at the threshold, J Clin Oncol, 11, pp. 1629-1635, (1993)
[6]
Lum, Kaubisch, Yahanda, Et al., Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance, J Clin Oncol, 10, pp. 1635-1642, (1992)
[7]
Bartlett, Lum, Fisher, Et al., Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance., J Clin Oncol, 12, pp. 835-842, (1994)
[8]
Lum, Kaubisch, Adler, Et al., Enhanced leukopenia by cyclosporine in a phase I clinical trial of modulation of etoposide resistance: pharmacokinetic and pharmacodynamic analysis, Proc Am Assoc Cancer Res, 33, (1992)
[9]
List, Spier, Greer, Et al., PhaseI/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia, J Clin Oncol, 11, pp. 1652-1660, (1993)
[10]
Erlichman, Moore, Thiessen, Et al., Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin, Cancer Res, 53, pp. 4837-4842, (1993)